Investigen Files Provisional Patent for smartDNA, A New DNA Detection and Diagnostic Process Offering Near Instantaneous Results.Business Editors HERCULES, Calif.--(BUSINESS WIRE)--June 23, 2003 Investigen, Inc., a leading innovator in multi-platform DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. diagnostics and the detection of genetically modified organisms The detection of genetically modified organisms (GMOs) in food or feed is possible by biochemical means. It can either be qualitative, showing which GMO is present, or quantitative, measuring in which amount a certain GMO is present. , today announced it has filed a provisional patent for its smartDNA(TM) diagnostic technology, a revolutionary, portable test process designed to identify DNA/RNA in minutes. Investigen is currently researching and developing applications for its smartDNA solution, and is actively seeking global partners to package and market smartDNA for commercial applications. smartDNA is ideal for on-site detection and identification of genetic disorders, infectious diseases, cancer, food- or water-borne pathogens, agro- and bio-terror agents, and related detection applications. This innovative, proprietary technology offers a rapid and sensitive diagnostic test that detects nucleic acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. sequences in minutes with minimal effort. smartDNA is faster and easier than other solutions available on the market today. Investigen's breakthrough testing technology will reduce the dependency on other expensive and cumbersome DNA test methods and will put DNA testing DNA testing Analysis of DNA (the genetic component of cells) in order to determine changes in genes that may indicate a specific disorder. Mentioned in: Acoustic Neuroma, Retinoblastoma, Von Willebrand Disease in a portable package that delivers near instantaneous results. "One area that we feel is ideally suited to smartDNA is the growing field of theranostics, the clinical integration of diagnostics and therapeutics. Working with pharmaceutical companies we will develop smartDNA tests to help identify patients with genetic profiles most likely to benefit from specific drug therapy regimens," said Dr. Heather Koshinsky, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Investigen. "Because smartDNA has such broad application beyond theranostics we are seeking global leaders in all areas of detection to partner in the development and distribution of smartDNA applications." Investigen expects to release the first smartDNA test kit before the end of this year. About Investigen Founded in 1998, Investigen, Inc., is an innovator in DNA testing, developing new processes to shorten testing time and reduce the cost of DNA diagnostic testing Diagnostic testing Testing performed to determine if someone is affected with a particular disease. Mentioned in: Von Willebrand Disease and detection of microorganisms and genetically modified organisms ge·net·i·cal·ly modified organism n. Abbr. GMO An organism whose genetic characteristics have been altered by the insertion of a modified gene or a gene from another organism using the techniques of genetic engineering. . Investigen has already developed tests for food quality assurance, health care, environmental safety, and industry. Investigen, Inc. has its corporate and its research headquarters at 750 Alfred Nobel Drive, Hercules CA 94547. www.investigen.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion